- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004753
Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease
OBJECTIVES: I. Correlate clinical outcome with cerebral glucose metabolism in patients with Huntington's disease (HD) and their at-risk relatives.
II. Evaluate the efficacy of cerebral glucose metabolism in observing the pathophysiologic development of HD, monitoring responses to experimental therapy, and predicting HD genotype.
III. Identify, define, and describe the natural history of pathophysiologic lesions in HD.
IV. Characterize the genotypic and phenotypic expression of the HD gene.
Study Overview
Status
Conditions
Detailed Description
PROTOCOL OUTLINE: Participants are screened for Huntington's disease, including cerebral glucose metabolism assessment and genetic testing.
Studies include a detailed family history and neurologic, psychometric, and neurobehavioral evaluations. Imaging includes positron emission tomography with fluorodeoxyglucose and brain magnetic resonance imaging.
A genotype assessment is performed; genetic results are not disclosed to patients or relatives.
Study Type
Enrollment
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Documented family history of Huntington's disease (HD)
- Symptomatic HD: chorea required
- At-risk for HD: no detectable systemic or oculomotor abnormality
- Age-matched control subjects
- No history of inherited neurological disease
- No general or neurologic abnormality
--Prior/Concurrent Therapy--
At least 4 weeks since other HD treatment, e.g.:
- Haloperidol
- Benzodiazepine
- Other tranquilizers or neuroleptics
--Patient Characteristics--
- No pregnant women
Study Plan
How is the study designed?
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: John C. Mazziotta, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Dyskinesias
- Heredodegenerative Disorders, Nervous System
- Dementia
- Cognition Disorders
- Chorea
- Huntington Disease
Other Study ID Numbers
- 199/11677
- UCLA-90063784
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Huntington's Disease
-
Massachusetts General HospitalCompletedHuntington's Disease (HD)United States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
SOM Innovation Biotech SACompleted
-
Sanguine BiosciencesHoffmann-La RocheRecruitingHuntington Disease | Huntington's Dementia | Huntington Disease, Late Onset | Huntington; Dementia (Etiology)United States
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
-
PfizerMedivation, Inc.CompletedHuntington Disease | Alzheimer's DiseaseUnited States
-
Hoffmann-La RocheCompleted
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States
-
PfizerMedivation, Inc.CompletedAlzheimer's Disease | Huntington's DiseaseUnited States